ATLANTA, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer of Alimera, will present at the following investor conferences in September:
- The Stifel Nicolaus Healthcare Conference to be held September 7 – 9, 2011 at The Four Seasons Hotel in Boston, MA. Mr. Myers is scheduled to present on September 8th at 8:35 A.M. ET.
- The Rodman & Renshaw Annual Investment Conference to be held September 11 – 13, 2011 at The Waldorf-Astoria Hotel in New York City. Mr. Myers is scheduled to present on September 13th at 10:25 A.M. ET.
The presentations with accompanying slides will be webcast live and can be accessed on the Investor Relations section of the corporate website at www.alimerasciences.com. For those who are not available to listen to the live broadcasts, the Stifel presentation webcast will be archived for 30 days and the Rodman presentation webcast will be archived for 90 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an investigational intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.